The first real clinical test of the cancer immunotherapy combination thesis has come back negative.

Incyte said Friday that its experimental drug epacadostat failed to improve the efficacy of Merck’s checkpoint inhibitor Keytruda when the two drugs were used together to treat patients with newly diagnosed melanoma.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • THANK GOD this episode of corporate mass hysteria is over. A drug that failed a monotherapy trial, only had single-arm add-on non-comparative data for itself (= nothing), and “pre-clinical efficacy” at 10x human doses in cherry-picked cell lines, has been rushed into God knows how many trials just for p-hacking purposes and hailed as the philosophical stone.

    I’m sorry for patients that such bogus projects are allowed to vacuum shareholder/taxpayer dollars, but since they are, the sooner these “experiments” are killed the better for biomedicine.

    Moral of the story : (1) pre-clinical and pharmacokinetics matter and (2) regulators should apply more Darwinian love to the pipeline.

  • Don’t discourage the keytruda method of cancer treatment keytruda is taking away all my squamous cancer in my face it has been a blessing to me

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy